Lab-grown meat: you may find it icky, but it could drive forward medical research 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Kennedy Sets September Deadline to Uncover Autism Causes Amid Controversy 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 
Japan PMI Data Signals Manufacturing Stabilization as Services Continue to Drive Growth 
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Oil Prices Rebound as Trump Orders Blockade of Sanctioned Venezuelan Tankers 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
